Clinical and pharmacoeconomic aspects of omalizumab: A 4-year follow-up

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 2, 2012, Pages 87-95

  Menzella, Francesco ^a   Facciolongo, Nicola ^a   Piro, Roberto ^a   Formisano, Debora ^a   Roggeri, Alberto ^a   Simonazzi, Anna ^a   Castagnetti, Claudia ^a   Carbonelli, Cristiano ^a   Zucchi, Luigi ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

asthma; efficacy; omalizumab; quality of life

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; STEROID; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; ECONOMICS, PHARMACEUTICAL; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 84859358781     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811429478     Document Type: Article

References (26)

1. Brown R. Turk F. Dale P. Bousquet J. (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62: 149–153.
2. Brusselle G. Michils A. Louis R. Dupont L. Van de Maele B. Delobbe A. (2009) “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 103: 1633–1642.
3. Campbell J.D. Spackman D.E. Sullivan S.D. (2010) The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 65: 1141–1148.
4. Cazzola M. Camiciottoli G. Bonavia M. Gulotta C. Ravazzi A. Alessandrini A. (2010) Italian real-life experience of omalizumab. Respir Med 104: 1410–1416.
5. Dewilde S. Turk F. Tambour M. Sandström T. (2006) The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 22: 1765–1776.
6. Frois C. Wu E.Q. Ray S. Colice G.L. (2009) Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 31: 2779–2803.
7. Global Initiative for Asthma (2006) GINA Global Strategy for Asthma Management and Prevention, 2006. NHI Publications No 02-3659.
8. Global Initiative for Asthma (2009) GINA update 2009. http://www.ginasthma.org.
9. Hamilton R.G. Marcotte G.V. Saini S.S. (2005) Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Meth 303: 81–91.
10. Hayashi N. Tsukamoto Y. Sallas W.M. Lowe P.J. (2006) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63: 548–561.
11. Humbert M. Beasley R. Ayres J. Slavin R. Hébert J. Bousquet J. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309–316.
12. Humbert M. Berger W. Rapatz G. Turk F. (2008) Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 63: 592–596.
13. Juniper E.F. Guyatt G.H. Ferrie P.J. Griffith L.E. (1993) Measuring quality of life in asthma. Am Rev Respir Dis 147: 832–838.
14. Lloyd A. Turk F. Leighton T. Canonica G.W. (2007) Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ 10: 285–296.
15. Loddenkemper R. Gibson G.J. Sybille Y. (2003) The first comprehensive survey on respiratory health in Europe. In: European Lung White Book. Sheffield: European Respiratory Society, pp. 16–25.
16. Ministero della Sanità (1996) Nomenclatore tariffario delle prestazioni ambulatoriali DM 22.07.96; Gazzetta Ufficiale n° 216 del 14.09.1996.
17. Ministero della Sanità (2006) Decreto del Minisetro della Sanità del 12 settembre 2006 (Suppl. Ord n. 234. G.U. n. 289 del 13 dicembre 2006).
18. National Heart, Lung, and Blood Institute (2002) Morbidity and Mortality: 2002. Bethesda, MD: National Heart, Lung, and Blood Institute.
19. Nopp A. Johansson S.G. Adédoyin J. Ankerst J. Palmqvist M. Oman H. (2010) After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 65: 56–60.
20. Oba Y. Salzman G.A. (2004) Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 114: 265–269.
21. Pace E. Ferraro M. Bruno A. Bousquet J. Gjomarkaj M. (2010) Anti-inflammatory effects of seven years treatment with omalizumab in severe uncontrolled asthmatics. Allergy 65: 1495–1496.
22. Pace E. Ferraro M. Bruno A. Chiappara G. Bousquet J. Gjomarkaj M. (2011) Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 48: 387–392.
23. Rodrigo G.J. Neffen H. Castro-Rodriguez J.A. (2011) Efficacy and safety of subcutaneous omalizumab versus placebo as add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139: 28–35.
24. Steiss J.O. Strohner P. Zimmer K.P. Lindemann H. (2008) Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 45: 233–236.
25. Walker S. Monteil M. Phelan K. Lasserson T.J. Walters E.H. (2006) Anti-IgE for chronic asthma in adults and children. Cochrane Database Systematic Rev 19: CD003559.
26. Wu A.C. Paltiel A.D. Kuntz K.M. Weiss S.T. Fuhlbrigge A.L. (2007) Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 120: 1146–1152.